aussie healthcare

After announcing soft guidance, a spin off of its vaccines unit, and plans to cut 3000 jobs, investors are pondering CSL's future.

There are several very good reasons why now is an ideal time to favour active investing over passive investing

The KP Rx Healthcare Opportunities Fund is targeting Australia & New Zealand's most innovative healthcare companies. Find out how they do it

There are two parts of the market we believe are setting up for strong returns in 2024: Small caps and Healthcare.

The ASX 200 followed strong overseas leads to log a modest gain as all sectors but Energy prospered.

IML's Hugh Giddy bought more of this stock a little over a year ago, and he has no intentions of selling after today's results.

In this episode, Wilson Asset Management's Tobias Yao and Tyndall Asset Management's Tim Johnston analyse five small-cap healthcare stocks.

The below takes a look at six ASX pharma and biotech stocks that experienced significant share price moves through the month as important news flow came through. 1)...

Despite some negative performers, there were still a number of companies that experienced significant share price gains.

Rumours of a private equity takeover were the story of 2022 for this company. What will 2023 bring?